Literature DB >> 19897009

The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Motoyasu Saji1, Matthew D Ringel.   

Abstract

The phosphoinositide-3 (OH) kinase (PI3K) signaling cascade is involved in regulating glucose uptake and metabolism, growth, motility, and other essential functions for cell survival. Unregulated activation of this pathway commonly occurs in cancer through a variety of mechanisms, including genetic mutations of kinases and regulatory proteins, epigenetic alterations that alter gene expression and translation, and posttranslational modifications. In thyroid cancer, constitutive activation of PI3K signaling has been shown to play a role in the genetic predisposition for thyroid neoplasia in Cowden's syndrome, and is recognized to be frequently overactivated in sporadic forms of thyroid cancer including those with aggressive clinical behaviors. In this review, the key signaling molecules in the PI3K signaling cascade, the abnormalities known to occur in thyroid cancer, and the potential for therapeutic targeting of PI3K pathway members will be discussed. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897009      PMCID: PMC2849843          DOI: 10.1016/j.mce.2009.10.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  160 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

2.  Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site.

Authors:  K Nakatani; H Sakaue; D A Thompson; R J Weigel; R A Roth
Journal:  Biochem Biophys Res Commun       Date:  1999-04-21       Impact factor: 3.575

3.  Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2.

Authors:  Y Mitsuuchi; S W Johnson; G Sonoda; S Tanno; E A Golemis; J R Testa
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

4.  Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3.

Authors:  S Masure; B Haefner; J J Wesselink; E Hoefnagel; E Mortier; P Verhasselt; A Tuytelaars; R Gordon; A Richardson
Journal:  Eur J Biochem       Date:  1999-10-01

5.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

6.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

7.  Akt1 contains a functional leucine-rich nuclear export sequence.

Authors:  Motoyasu Saji; Vasily Vasko; Faiza Kada; Elena Hardy Allbritton; Kenneth D Burman; Matthew D Ringel
Journal:  Biochem Biophys Res Commun       Date:  2005-06-24       Impact factor: 3.575

8.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Authors:  Maria Letizia Motti; Daniela Califano; Giancarlo Troncone; Carmela De Marco; Ilenia Migliaccio; Emiliano Palmieri; Luciano Pezzullo; Lucio Palombini; Alfredo Fusco; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

9.  Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

Authors:  Yuko Kawakami; Hajime Nishimoto; Jiro Kitaura; Mari Maeda-Yamamoto; Roberta M Kato; Dan R Littman; Michael Leitges; David J Rawlings; Toshiaki Kawakami
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

Review 10.  Signalling by PI3K isoforms: insights from gene-targeted mice.

Authors:  Bart Vanhaesebroeck; Khaled Ali; Antonio Bilancio; Barbara Geering; Lazaros C Foukas
Journal:  Trends Biochem Sci       Date:  2005-04       Impact factor: 13.807

View more
  67 in total

1.  Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.

Authors:  Ning Jin; Tianyun Jiang; David M Rosen; Barry D Nelkin; Douglas W Ball
Journal:  Clin Cancer Res       Date:  2011-08-10       Impact factor: 12.531

2.  GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation.

Authors:  Hong Soon Kang; Dhirendra Kumar; Grace Liao; Kristin Lichti-Kaiser; Kevin Gerrish; Xiao-Hui Liao; Samuel Refetoff; Raja Jothi; Anton M Jetten
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

3.  Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.

Authors:  Zorica Milošević; Jasna Banković; Jelena Dinić; Chrisiida Tsimplouli; Evangelia Sereti; Miodrag Dragoj; Verica Paunović; Zorka Milovanović; Marija Stepanović; Nikola Tanić; Kostantinos Dimas; Milica Pešić
Journal:  Cell Oncol (Dordr)       Date:  2018-05-22       Impact factor: 6.730

Review 4.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 5.  Role of retinoids in the prevention and treatment of colorectal cancer.

Authors:  Catherine C Applegate; Michelle A Lane
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

6.  Analysis of exosome release as a cellular response to MAPK pathway inhibition.

Authors:  K Agarwal; M Saji; S M Lazaroff; A F Palmer; M D Ringel; M E Paulaitis
Journal:  Langmuir       Date:  2015-05-05       Impact factor: 3.882

Review 7.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

8.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16

9.  Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.

Authors:  Hyoung-Sook Park; Jong-Wan Park; Hye-Jin Kim; Chang Won Choi; Hyun-Ju Lee; Byung Il Kim; Yang-Sook Chun
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-11       Impact factor: 6.914

Review 10.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.